Detection of N-Ras codon 61 mutations in subpopulations of tumor cells in multiple myeloma at presentation

被引:36
作者
Kalakonda, N
Rothwell, DG
Scarffe, JH
Norton, JD
机构
[1] Paterson Inst Canc Res, CRC, Gene Regulat Grp, Manchester M20 9BX, Lancs, England
[2] Christie Hosp NHS Trust, Dept Med Oncol, CRC, Manchester M20 4BX, Lancs, England
关键词
D O I
10.1182/blood.V98.5.1555
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Activating point mutations in codons 12, 13, or 61 of the K-ras and N-ras genes have been reported to occur in up to 40% of patients with multiple myeloma at presentation. In a study of 34 presentation myeloma cases using a sensitive polymerase chain reaction-restriction fragment length polymorphism strategy on enriched tumor cell populations, the present study detected N-ras codon 61 mutation-positive cells In all patients. Quantitative plaque hybridization using allele-specific oligonucleotide probes showed that in the majority of patients, ras mutation-positive cells comprise only a subpopulation of the total malignant plasma cell compartment (range, 12%-100%). Using clonospecific point mutations in the 5 ' untranslated region of the BCL6 gene to quantitate clonal B cells in FACS-sorted bone marrow populations from 2 patients, the representation of ras mutation-positive cells was independent of immunophenotype. These observations imply that mutational activation of N-ras codon 61 is a mandatory event in the pathogenesis of multiple myeloma; such mutations provide a marker of intraclonal heterogeneity that may originate at an earlier ontologic stage than immunophenotypic diversification of the malignant B cell clone. (C) 2001 by The American Society of Hematology.
引用
收藏
页码:1555 / 1560
页数:6
相关论文
共 33 条
[1]   WHO BENEFITS FROM HIGH-DOSE THERAPY FOR MULTIPLE-MYELOMA [J].
ANDERSON, KC .
JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (06) :1291-1296
[2]   A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma [J].
Attal, M ;
Harousseau, JL ;
Stoppa, AM ;
Sotto, JJ ;
Fuzibet, JG ;
Rossi, JF ;
Casassus, P ;
Maisonneuve, H ;
Facon, T ;
Ifrah, N ;
Payen, C ;
Bataille, R .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (02) :91-97
[3]  
Berenson JR, 1999, SEMIN HEMATOL, V36, P9
[4]  
Billadeau D, 1997, CANCER RES, V57, P2268
[5]  
BILLADEAU D, 1995, CANCER RES, V55, P3640
[6]  
BROWETT PJ, 1989, ONCOGENE, V4, P1029
[7]   Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3 [J].
Chesi, M ;
Nardini, E ;
Brents, LA ;
Schrock, E ;
Ried, T ;
Kuehl, WM ;
Bergsagel, PL .
NATURE GENETICS, 1997, 16 (03) :260-264
[8]   Frequent dysregulation of the c-maf proto-oncogene at 16q23 by translocation to an Ig locus in multiple myeloma [J].
Chesi, M ;
Bergsagel, PL ;
Shonukan, OO ;
Martelli, ML ;
Brents, LA ;
Chen, T ;
Schröck, E ;
Ried, T ;
Kuehl, VM .
BLOOD, 1998, 91 (12) :4457-4463
[9]  
CORRADINI P, 1994, LEUKEMIA, V8, P758
[10]  
CORRADINI P, 1993, BLOOD, V81, P2708